Is Prime Boost Strategy a Promising Approach in HIV Vaccine Development?
- *Corresponding Author:
- Paranjape RS
Director, National AIDS Research Institute
Indian Council of Medical Research
73, G block, MIDC, Bhosari
E-mail: [email protected]
Received Date: February 27, 2014; Accepted Date: April 11, 2014; Published Date: April 21, 2014
Citation: Shete A, Thakar M, Mehendale SM, Paranjape RS (2014) Is Prime Boost Strategy a Promising Approach in HIV Vaccine Development? J AIDS Clin Res 5:293. doi:10.4172/2155-6113.1000293
Copyright: © 2014 Shete A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author andsource are credited.
Since the discovery of HIV vaccine three decades back, the quest for HIV vaccines has remained unquenched. There has been a transition of preferred approaches from candidates capable of inducing neutralizing antibody (Nab) or cytolytic T cell (CTL) response to vaccines that can induce broad spectrum responses. Heterologous prime boost strategy is believed to induce broad spectrum immunity of higher magnitude and breadth to effectively counter HIV diversity and hence is being studied extensively in the HIV vaccine field. It is important to understand factors affecting the immune responses generated by the prime-boost regimens to get leads for developing effective regimens. This review focuses on the results of completed clinical trials based on the three most frequently used prime-boost regimens, vector (ALVAC)/protein, DNA/vector (MVA) and DNA/vector (Ad5). It will also discuss probable protective immunological responses responsible for efficacy of the vaccine and role of prime boost strategy in eliciting them.